Somatic Copy-Number Alterations in Plasma Circulating Tumor DNA from Advanced EGFR-Mutated Lung Adenocarcinoma Patients.
Acrylamides
/ therapeutic use
Adenocarcinoma
/ pathology
Adenocarcinoma of Lung
/ genetics
Aged
Aged, 80 and over
Aniline Compounds
/ therapeutic use
Biomarkers, Pharmacological
/ blood
Carcinoma, Non-Small-Cell Lung
/ pathology
Cell-Free Nucleic Acids
/ blood
Circulating Tumor DNA
/ genetics
DNA Copy Number Variations
/ genetics
Drug Resistance, Neoplasm
/ genetics
ErbB Receptors
/ genetics
Female
Humans
Liquid Biopsy
/ methods
Lung
/ pathology
Lung Neoplasms
/ genetics
Male
Middle Aged
Progression-Free Survival
Protein Kinase Inhibitors
/ therapeutic use
EGFR mutations
NSCLC
ctDNA
osimertinib
somatic copy-number alterations
Journal
Biomolecules
ISSN: 2218-273X
Titre abrégé: Biomolecules
Pays: Switzerland
ID NLM: 101596414
Informations de publication
Date de publication:
21 04 2021
21 04 2021
Historique:
received:
11
03
2021
revised:
08
04
2021
accepted:
16
04
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
22
9
2021
Statut:
epublish
Résumé
To assess the clinical relevance of genome-wide somatic copy-number alterations (SCNAs) in plasma circulating tumor DNA (ctDNA) from advanced epidermal growth factor receptor ( We included 43 patients with advanced SCNAs in resistance-related genes (rrSCNAs) were detected in 10 out of 31 (32%) evaluable patients before start of osimertinib. The presence of rrSCNAs in plasma before the initiation of osimertinib therapy was associated with a lower response rate to osimertinib (50% versus 81%, Genomic profiling of plasma ctDNA is clinically relevant and affects the efficacy and clinical outcome of osimertinib. Our approach enables the comprehensive assessment of SCNAs in plasma samples of lung adenocarcinoma patients and may help to guide genotype-specific therapeutic strategies in the future.
Sections du résumé
BACKGROUND
To assess the clinical relevance of genome-wide somatic copy-number alterations (SCNAs) in plasma circulating tumor DNA (ctDNA) from advanced epidermal growth factor receptor (
METHODS
We included 43 patients with advanced
RESULTS
SCNAs in resistance-related genes (rrSCNAs) were detected in 10 out of 31 (32%) evaluable patients before start of osimertinib. The presence of rrSCNAs in plasma before the initiation of osimertinib therapy was associated with a lower response rate to osimertinib (50% versus 81%,
CONCLUSIONS
Genomic profiling of plasma ctDNA is clinically relevant and affects the efficacy and clinical outcome of osimertinib. Our approach enables the comprehensive assessment of SCNAs in plasma samples of lung adenocarcinoma patients and may help to guide genotype-specific therapeutic strategies in the future.
Identifiants
pubmed: 33919291
pii: biom11050618
doi: 10.3390/biom11050618
pmc: PMC8143372
pii:
doi:
Substances chimiques
Acrylamides
0
Aniline Compounds
0
Biomarkers, Pharmacological
0
Cell-Free Nucleic Acids
0
Circulating Tumor DNA
0
Protein Kinase Inhibitors
0
osimertinib
3C06JJ0Z2O
EGFR protein, human
EC 2.7.10.1
ErbB Receptors
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Bundesministerium für Digitalisierung und Wirtschaftsstandort
Références
Ann Oncol. 2015 Oct;26(10):2073-8
pubmed: 26269204
Nat Commun. 2017 Nov 6;8(1):1324
pubmed: 29109393
J Clin Oncol. 2020 Jan 10;38(2):124-136
pubmed: 31411950
Int J Cancer. 2018 Sep 1;143(5):1236-1248
pubmed: 29574703
Cancer Res. 2017 Apr 15;77(8):2078-2089
pubmed: 28202511
J Thorac Oncol. 2017 Mar;12(3):567-572
pubmed: 27923714
N Engl J Med. 2017 Feb 16;376(7):629-640
pubmed: 27959700
Lung Cancer. 2018 Jan;115:21-27
pubmed: 29290257
J Thorac Oncol. 2018 Sep;13(9):1415-1421
pubmed: 29857056
Nat Genet. 2017 Dec;49(12):1693-1704
pubmed: 29106415
J Thorac Oncol. 2018 Jun;13(6):821-830
pubmed: 29505901
Clin Cancer Res. 2018 Jul 1;24(13):3097-3107
pubmed: 29506987
J Thorac Oncol. 2018 Jun;13(6):e89-e91
pubmed: 29596911
JAMA Oncol. 2018 Nov 1;4(11):1527-1534
pubmed: 30073261
Transl Lung Cancer Res. 2020 Apr;9(2):239-245
pubmed: 32420063
J Thorac Oncol. 2015 Dec;10(12):1736-44
pubmed: 26473643
Curr Opin Oncol. 2016 Mar;28(2):130-4
pubmed: 26730486
Nat Med. 2015 Jun;21(6):560-2
pubmed: 25939061
PLoS Genet. 2014 Mar 27;10(3):e1004271
pubmed: 24676216
J Thorac Oncol. 2016 Sep;11(9):e105-7
pubmed: 27086175
Nat Rev Genet. 2019 Feb;20(2):71-88
pubmed: 30410101
Lancet Oncol. 2016 Dec;17(12):1643-1652
pubmed: 27751847
J Clin Oncol. 2018 Mar 20;36(9):841-849
pubmed: 28841389
Target Oncol. 2019 Feb;14(1):75-83
pubmed: 30539501
N Engl J Med. 2015 Apr 30;372(18):1689-99
pubmed: 25923549
N Engl J Med. 2018 Jan 11;378(2):113-125
pubmed: 29151359
Clin Cancer Res. 2018 Jul 1;24(13):3108-3118
pubmed: 29530932
Clin Cancer Res. 2018 Dec 15;24(24):6195-6203
pubmed: 30228210
Oncotarget. 2017 Jul 25;8(30):49671-49679
pubmed: 28572531
Clin Cancer Res. 2016 Oct 1;22(19):4837-4847
pubmed: 27252416
Target Oncol. 2019 Apr;14(2):197-203
pubmed: 30810887
J Thorac Oncol. 2016 Jan;11(1):e1-4
pubmed: 26762749
Cancer Res. 2019 Feb 15;79(4):689-698
pubmed: 30718357
Nat Commun. 2016 Jun 22;7:12008
pubmed: 27328849
Genome Med. 2013 Apr 05;5(4):30
pubmed: 23561577
Lung Cancer. 2016 Aug;98:59-61
pubmed: 27393507
Clin Cancer Res. 2019 Apr 1;25(7):2058-2063
pubmed: 30659024
Cancer Res. 2015 Jun 15;75(12):2489-500
pubmed: 25870145
Lung Cancer. 2017 Jun;108:238-241
pubmed: 28625643
J Thorac Oncol. 2017 Jan;12(1):15-26
pubmed: 27794501
J Clin Oncol. 2020 Jan 10;38(2):115-123
pubmed: 31682542